Fever News and Research

RSS

Vertex announces 16 grant recipients of Hep-C Circle of Care program

Vertex Pharmaceuticals Incorporated today announced that it has awarded 16 grants totaling approximately $1.5 million to a variety of academic, patient and community groups as part of the Vertex Hep-C Circle of Care program, a pilot competitive grants program designed to foster innovative approaches to patient care and support people living with chronic hepatitis C.

5 Nov 2011

Reduced diversity of intestinal microbiota associated with increased risk of allergic disease

Oversensitivity diseases, or allergies, now affect 25 per cent of the population of Denmark. The figure has been on the increase in recent decades and now researchers at the Copenhagen Prospective Studies on Asthma in Childhood (COPSAC), University of Copenhagen, are at last able to partly explain the reasons.

3 Nov 2011

Study outlines evolution of malaria, leishmaniasis and trypanosomiasis

One of the most comprehensive analyses yet done of the ancient history of insect-borne disease concludes for the first time that malaria is not only native to the New World, but it has been present long before humans existed and has evolved through birds and monkeys.

3 Nov 2011

EBV vaccine could prevent mononucleosis and cancers linked to virus

In a new article from the National Institutes of Health (NIH), Anthony S. Fauci, M.D., director of the National Institute of Allergy and Infectious Diseases (NIAID), and Harold Varmus, M.D., director of the National Cancer Institute (NCI), join Gary Nabel, M.D., Ph.D., director of NIAID's Vaccine Research Center, and Jeffrey Cohen, M.D., chief of NIAID's Laboratory of Infectious Diseases, in summarizing a recent meeting of experts who gathered to map directions toward an EBV vaccine.

3 Nov 2011

Elevated body temperature helps certain types of immune cells to work better

With cold and flu season almost here, the next time you're sick, think twice before taking something for your fever. That's because scientists have found more evidence that elevated body temperature helps certain types of immune cells to work better.

2 Nov 2011

Takeda receives FDA approval for VELCADE sNDA to treat MM

Millennium: The Takeda Oncology Company with its parent company Takeda Pharmaceutical Company Limited today announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental new drug application (sNDA) for VELCADE (bortezomib) for Injection, which updates the label to include additional long-term overall survival (OS) data from the VISTA trial.

2 Nov 2011

GM mosquitoes show promise in tackling insect-borne diseases, study shows; some concerned over possible unintended consequences

"Genetically modified mosquitoes could prove effective in tackling dengue fever and other insect-borne diseases," according to the results of a study by a U.K.-based scientific team published in the journal Nature Biotechnology on Sunday, BBC News reports.

2 Nov 2011

iBio receives U.S. patent entitled 'System for Expression of Genes in Plants'

iBio, Inc. today announced notice of issuance from the United States Patent and Trademark Office for US Patent 8,058,511, entitled "System for Expression of Genes in Plants," that further extends iBio's patent coverage of viral vectors comprising its iBioLaunch platform.

1 Nov 2011

UCB to present new data on Cimzia at ACG annual scientific meeting

UCB, a leading biopharmaceutical company at the forefront of immunology treatment and research, will present new data on Cimzia at the American College of Gastroenterology (ACG) Annual Scientific Meeting, taking place in Washington D.C. from October 28 to November 2.

1 Nov 2011

EC approves Lilly's ALIMTA as continuation maintenance therapy for NSCLC

Eli Lilly and Company announced today that the European Commission has granted approval for the use of ALIMTA (pemetrexed for injection) as a single agent for continuation maintenance therapy in patients with a particular type of lung cancer, called advanced nonsquamous non-small cell lung cancer

29 Oct 2011

New discoveries on drug resistance in Leishmania

Two remarkable discoveries were today revealed by researchers into genome analysis of Leishmania parasites. These results uncovered a surprising level of variation at the genome structure level.

28 Oct 2011

Gilead, Bristol-Myers Squibb to develop and commercialize fixed-dose combination for HIV

Bristol-Myers Squibb Company and Gilead Sciences, Inc. today announced a licensing agreement for Bristol-Myers Squibb to develop and commercialize a fixed-dose combination containing Bristol-Myers Squibb's protease inhibitor REYATAZ (atazanavir sulfate) and Gilead's cobicistat, a pharmacoenhancing or "boosting" agent that increases blood levels of certain HIV medicines to potentially allow for one pill once daily dosing.

27 Oct 2011

Lundbeck's ONFI receives FDA approval for treating seizures associated with Lennox-Gastaut syndrome

Lundbeck Inc., a wholly owned subsidiary of H. Lundbeck A/S in Denmark, announced today that the U.S. Food and Drug Administration (FDA) has approved ONFI as adjunctive therapy for seizures associated with Lennox-Gastaut syndrome in patients two years and older.

24 Oct 2011

Vertex initiates INCIVEK combination Phase 3b study for hepatitis C

Vertex Pharmaceuticals Incorporated today announced the initiation of a Phase 3b study called CONCISE that will evaluate the potential for treatment with INCIVEK (telaprevir) combination therapy to be shortened to 12 weeks in people with genotype 1 chronic hepatitis C who have the 'CC' variation near the IL28B gene.

24 Oct 2011

SafeMinds praises UNEP's draft treaty ban on use of mercury in pharma products

SafeMinds applauds UNEP's draft treaty language which does not exempt the use of mercury in pharmaceutical products, including vaccines, from the global ban. Governmental regulators, public health officials and pharmaceutical companies have recognized that the toxicity of mercury in pharmaceutical and personal care products, to which people are directly exposed, justifies a preventive approach to minimize all exposures.

24 Oct 2011

Pivotal pediatric clinical study comparing Q/LAIV to FluMist meets primary endpoint

The pivotal pediatric clinical study compared Q/LAIV to two trivalent formulations of MedImmune's licensed seasonal influenza vaccine, FluMist (Influenza Vaccine Live, Intranasal) and met its primary endpoint.

22 Oct 2011

Pfizer's Prevnar 13: Additional data from adult clinical studies presented at 49th IDSA

Pfizer Inc. announced today that additional data from several clinical studies of Prevnar 13 (Pneumococcal 13-valent Conjugate Vaccine) conducted in adults 50 years and older will be presented during the 49th Annual Meeting of the Infectious Diseases Society of America, which is being held Oct. 20-23, 2011, in Boston, Mass.

22 Oct 2011

Janssen announces FDA label update approval for PREZISTA HIV tablets

Janssen Therapeutics, Division of Janssen Products, LP, announced today that the U.S. Food and Drug Administration (FDA) has approved a label update for PREZISTA (darunavir) tablets to include 192-week data from the ARTEMIS study.

22 Oct 2011

Romark announces results from NT-300 Phase 2B-3 trial on influenza

Romark Laboratories announced that results of a large Phase 2B-3 US clinical trial of its new flu drug, NT-300 (nitazoxanide), will be presented as an oral late-breaking communication at the 49th Annual Meeting of the Infectious Diseases Society of America (IDSA) being held in Boston, October 20-23, 2011.

22 Oct 2011

Wolbachia study reveals novel approaches to control insects transmitting deadly diseases

Researchers at Boston University have made discoveries that provide the foundation towards novel approaches to control insects that transmit deadly diseases such as dengue fever and malaria through their study of the Wolbachia bacteria.

21 Oct 2011

Fever News and Research

Vertex announces 16 grant recipients of Hep-C Circle of Care program

Reduced diversity of intestinal microbiota associated with increased risk of allergic disease

Study outlines evolution of malaria, leishmaniasis and trypanosomiasis

EBV vaccine could prevent mononucleosis and cancers linked to virus

Elevated body temperature helps certain types of immune cells to work better

Takeda receives FDA approval for VELCADE sNDA to treat MM

GM mosquitoes show promise in tackling insect-borne diseases, study shows; some concerned over possible unintended consequences

iBio receives U.S. patent entitled 'System for Expression of Genes in Plants'

UCB to present new data on Cimzia at ACG annual scientific meeting

EC approves Lilly's ALIMTA as continuation maintenance therapy for NSCLC

New discoveries on drug resistance in Leishmania

Gilead, Bristol-Myers Squibb to develop and commercialize fixed-dose combination for HIV

Lundbeck's ONFI receives FDA approval for treating seizures associated with Lennox-Gastaut syndrome

Vertex initiates INCIVEK combination Phase 3b study for hepatitis C

SafeMinds praises UNEP's draft treaty ban on use of mercury in pharma products

Pivotal pediatric clinical study comparing Q/LAIV to FluMist meets primary endpoint

Pfizer's Prevnar 13: Additional data from adult clinical studies presented at 49th IDSA

Janssen announces FDA label update approval for PREZISTA HIV tablets

Romark announces results from NT-300 Phase 2B-3 trial on influenza

Wolbachia study reveals novel approaches to control insects transmitting deadly diseases

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News